Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir

Jonas Schreiber, John McNally, Krishna Chodavarapu, Evguenia Svarovskaia, Christophe Moreno – 14 May 2016 – During a phase 3 study evaluating the combination of sofosbuvir‐velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64:983‐985)

Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir

Jonas Schreiber, John McNally, Krishna Chodavarapu, Evguenia Svarovskaia, Christophe Moreno – 14 May 2016 – During a phase 3 study evaluating the combination of sofosbuvir‐velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64:983‐985)

Chronic expression of interferon‐gamma leads to murine autoimmune cholangitis with a female predominance

Heekyong R. Bae, Patrick S.C. Leung, Koichi Tsuneyama, Julio C. Valencia, Deborah L. Hodge, Seohyun Kim, Tim Back, Megan Karwan, Anand S. Merchant, Nobuyuki Baba, Dechun Feng, Ogyi Park, Bin Gao, Guo‐Xiang Yang, M. Eric Gershwin, Howard A. Young – 14 May 2016 – In most autoimmune diseases the serologic hallmarks of disease precede clinical pathology by years. Therefore, the use of animal models in defining early disease events becomes critical.

Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression

Sandra Rebouissou, Andrea Franconi, Julien Calderaro, Eric Letouzé, Sandrine Imbeaud, Camilla Pilati, Jean‐Charles Nault, Gabrielle Couchy, Alexis Laurent, Charles Balabaud, Paulette Bioulac‐Sage, Jessica Zucman‐Rossi – 14 May 2016 – CTNNB1 mutations activating ß‐catenin are frequent somatic events in hepatocellular carcinoma (HCC) and adenoma (HCA), particularly associated with a risk of malignant transformation. We aimed to understand the relationship between CTNNB1 mutation types, tumor phenotype, and level of ß‐catenin activation in malignant transformation.

Hepatocellular carcinoma repression by TNFα‐mediated synergistic lethal effect of mitosis defect‐induced senescence and cell death sensitization

Dan Li, Jing Fu, Min Du, Haibin Zhang, Lu Li, Jin Cen, Weiyun Li, Xiaotao Chen, Yunfei Lin, Edward M. Conway, Eli Pikarsky, Hongyan Wang, Guoyu Pan, Yuan Ji, Hong‐Yang Wang, Lijian Hui – 14 May 2016 – Hepatocellular carcinoma (HCC) is a cancer lacking effective therapies. Several measures have been proposed to treat HCCs, such as senescence induction, mitotic inhibition, and cell death promotion. However, data from other cancers suggest that single use of these approaches may not be effective.

Subscribe to